CHARACTERIZATION OF ACTIVATED TUMOR-INFILTRATING B LYMPHOCYTES

Nadia Al-Banna1,2, Nicolas Boily2, Jean-Pierre Routy1, and Réjean Lapointe2.

1 McGill University Health Centre (MUHC), Montreal
2 Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CRCHUM), Montréal

Tumor-infiltrating B-lymphocytes (TIL-B), expressing CD19+ or CD20+, have been identified in several cancers. Although their presence frequently correlates with a positive clinical outcome, their heterogeneity and function are not well characterized.

**Aim:** To characterize the differentiation and activation status of TIL-B in lung and kidney tumors, and define their function.

**Methods:** PBMCs and TILs were isolated from same patients of lung or kidney cancer, and then stained for B cell differentiation and activation markers using flow cytometry (e.g. CD19, CD20, CD24, CD25, CD38, CD69, CD80, CD86, IgD) (n=5-10). In addition, B cells of cancer patients were in vitro cultured in simulating conditions (e.g. with sCD40L/IL-4) (n=5-7).

**Results:** Most circulating B cells were IgD+ cells, including 5% transitional memory CD24++ CD38++ cells, while lung and kidney TIL-B were equally further differentiated, being IgD- (60-70%) (p<0.05). In addition, more CD69+ and CD86+ cells, and fewer CD95+ expression is observed amongst IgD- TIL-B than circulating PBMCs (p<0.05), indicating the presence of recently activated B cells in the tumor. Increased activation is also supported by the presence of cytokine-producing cells and by the modulated expression of chemokine receptors (CXCR4, CCR6 and CCR10). In addition, we observed an enhanced expression of CD25, CD69, CD80 and CD86 (p<0.05), as activation markers, and the production of cytokines like TNF on in vitro cultured B cells.

**Conclusions:** B cells infiltrating tumors are more differentiated and activated when compared to circulating B cells in the same patient. Tumor-infiltrating B cells can be activated and expanded in vitro. Understanding the tumor-infiltrating B cells and standardizing method to expand competent B cells would promote the development of adoptive cell therapies against cancer.